ASX Announcement
13 November 2026

Ms Renee Hutchens
Adviser, ASX Listings Compliance (Sydney)
20 Bridge Street,
SYDNEY, NSW 2000

By email: tradinghaltssydney@asx.com.au

Request for a Trading Halt – Microba Life Sciences Limited (ASX: MAP)

Microba Life Sciences Limited (ASX: MAP) (**Microba**), requests an immediate trading halt be granted by ASX Limited in respect of its shares on Friday, 13 November 2026.

The trading halt is requested given proposed material changes to the terms of the proposed merger between Microba and Genetic Signatures Ltd (**Proposed Merger**).

In accordance with ASX Listing Rule 17.1, Microba provides the following information:

(a) the trading halt is necessary for Microba to make an announcement to the market in relation to the Proposed Merger;

(b) the trading halt should remain in place until the earlier of the commencement of trading on Tuesday, 17 November 2026 or such time that Microba makes an announcement to the market in relation to the Proposed Merger;

(c) Microba is not aware of any reason why the trading halt should not be granted; and

(d) Microba is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely,

James Heath
CFO & Company Secretary

This announcement has been authorised for release by the Board of Directors.

About Microba Life Sciences Limited
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com